News | February 13, 2021
Steady performance; for Alkem Laboratories: ICICI Securities
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
Be One is a 100% Ayurvedic health and wellness supplement.
Tavaborole Topical Solution, 5%, is an oxaborole antifungal.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
Subscribe To Our Newsletter & Stay Updated
